
Pulled from Benzinga Pro data, Avid Bioservices (NASDAQ:CDMO) showed a loss in earnings since Q2, totaling $2.25 million. Sales, on the other hand, increased by 20.68% to $31.51 million during Q3. In Q2, Avid Bioservices earned $3.52 million and total sales reached $26.11 million.